OTRAS NOTICIAS DE LAS ENFERMEDADES RARAS
High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our T&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights.
https://www.ft.com/content/cbb0c876-f77d-11e6-bd4e-68d53499ed71
Comment: Building cross-border healthcare networks
‘The implications will be huge, not just for patients, but also for the pharmaceuticals companies’
Read next
Orphan drugs attract rich returns for pharmaceuticals
Share on Twitter (opens new window)
Share on Facebook (opens new window)
Share on LinkedIn (opens new window)
0 Save
FEBRUARY 28, 2017 by: Yann Le Cam
One of the greatest challenges faced by those working to treat rare diseases is that the expertise and the very small groups of patients are scattered across the world. Even within Europe, it is very difficult to connect the right knowledge, treatment and research with the people who need it most.
https://www.ft.com/content/cbb0c876-f77d-11e6-bd4e-68d53499ed71
Comment: Building cross-border healthcare networks
‘The implications will be huge, not just for patients, but also for the pharmaceuticals companies’
Read next
Orphan drugs attract rich returns for pharmaceuticals
Share on Twitter (opens new window)
Share on Facebook (opens new window)
Share on LinkedIn (opens new window)
0 Save
FEBRUARY 28, 2017 by: Yann Le Cam
One of the greatest challenges faced by those working to treat rare diseases is that the expertise and the very small groups of patients are scattered across the world. Even within Europe, it is very difficult to connect the right knowledge, treatment and research with the people who need it most.
.png)
No hay comentarios:
Publicar un comentario